JYNT - NASDAQ
The Joint Corp.
$8.36
+0.54%The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
At a Glance
Live Snapshotjynt
Total Current Assets
Last Annual Value
52.09M
3-Year CAGR
44%
5-Year CAGR
15%
10-Year CAGR
11%
The Joint Corp. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
The Joint Corp. NASDAQ:JYNT | 52.09M | 5.5% | 14.1% | 24.8% | |
 biote Corp. NASDAQ:BTMD | 54.67M | -23.5% | 3.0% | N/A | |
 Inhibikase Therapeutics, Inc. NASDAQ:IKT | 180.11M | 133.2% | 33.5% | 116.3% | |
 CareCloud, Inc. NASDAQ:CCLD | 25.74M | 3.5% | -6.3% | 11.8% | |
 DocGo Inc. NASDAQ:DCGO | 152.40M | -23.4% | -9.9% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 4.62M | 3.6% | -4.0% | -5.2% | |
 Microbot Medical Inc. NASDAQ:MBOT | 79.82M | 116.0% | 38.1% | 37.5% | |
 Agenus Inc. NASDAQ:AGEN | 133.44M | 5.9% | -16.7% | 3.9% | |
 Anika Therapeutics, Inc. NASDAQ:ANIK | 103.36M | -14.1% | -9.3% | -4.9% | |
 Climb Bio, Inc. NASDAQ:CLYM | 105.85M | -1.4% | -6.5% | N/A | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 47.99M | 11.9% | -4.0% | N/A |
The Joint Corp. Fair Value Envelope
Related Guides
Continue your JYNT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.